๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hangzhou
Clinical trial register · China

Clinical Trials in Hangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 53 Beijing 25 Wuhan 15 Hangzhou 13 Nanjing 12
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai53 Beijing25 Wuhan15 Hangzhou13 Nanjing12
All 38 locations
Target enrolment
to

Trials with a site in Hangzhou

13 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer
NCT07736612Pancreatic Cancer, RAS Mutations or Amplifications
Zhejiang University
Phase 1/2
80
Hangzhou
2026-08-15
Active, closed
Research of the Application of Pancreatic Cancer Screening Artificial Intelligence Model "PANDAPro"
NCT06643715Pancreatic Cancer
Zhejiang University
Not applicable
100,000
Hangzhou
2026-03-07
Not yet open
IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer
NCT07415525Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma
DrugIBI343
Zhejiang University
Phase 2
40
Hangzhou
2026-02-01
Recruiting
LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
NCT07312422Pancreatic Cancer, PD-L1, PD-1 Inhibitor, LDRT
Zhejiang Provincial People's Hospital
Phase 1/2
10
Hangzhou
2025-09-30
Recruiting
A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
NCT06953999Pancreatic Cancer
Akeso
Phase 3
999
Harbin, Shanghai, Hangzhou
2025-06-11
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Hefei, Beijing, Guangzhou, Wuhan, Harbin, Changsha, Chengdu, Hangzhou
2025-01-29
Not yet open
Research of the Application of Artificial Intelligence Model "PANDA"
NCT06528223Pancreatic Cancer
Zhejiang University
Not applicable
200,000
Hangzhou
2024-08-15
Recruiting
Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
NCT06821048Colorectal Cancer, Stomach Cancer, Pancreatic Cancer, Metastatic Cancer
Weijia Fang, MD
Phase 1
18
Hangzhou
2024-07-24
Recruiting
Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers
NCT06139042Liver Cancer, Biliary Tract Cancer, Pancreatic Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
1,608
Hangzhou
2023-11-01
Not yet open
Canagliflozin With Gemcitabine in Pancreatic Carcinoma
NCT05903703Pancreatic Cancer
Zhang Xiaofeng,MD
Not applicable
20
Hangzhou
2023-10-01
Recruiting
A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
NCT05911217Pancreatic Cancer
CARsgen Therapeutics Co., Ltd.
Phase 1
20
Beijing, Zhengzhou, Wuhan, Changsha, Shanghai, Xian, Hangzhou
2023-07-11
Recruiting
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
NCT05859750Pancreatic Cancer
Akeso
Phase 2
78
Beijing, Guangzhou, Wuhan, Jinan, Shanghai, Hangzhou
2023-05-25
Recruiting
Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer
NCT03498326Pancreatic Cancer, Chemotherapy Effect
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
480
Hangzhou
2018-04-02
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/city/hangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies with a site in Hangzhou that also match the filters currently applied.

How many clinical trials are recruiting in Hangzhou?

7 of the 13 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 4 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hangzhou), 13 studies
PhaseStudiesRecruitingShare
Not applicable3023.1%
Phase 1/23123.1%
Phase 23223.1%
Phase 12215.4%
Observational117.7%
Phase 3117.7%

Most active sponsors

Lead sponsors with the most studies (Hangzhou)
Lead sponsorStudiesRecruiting
Zhejiang University40
Akeso22
Second Affiliated Hospital, Zhejiang University, School of Medicine22
CARsgen Therapeutics Co., Ltd.11
EMD Serono Research & Development Institute, Inc.10
Weijia Fang, MD11
Zhang Xiaofeng,MD10
Zhejiang Provincial People's Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.